BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $830,590 | -17.3% | 12,202 | -0.8% | 0.01% | -8.3% |
| Q2 2023 | $1,004,212 | +11.7% | 12,302 | +1.5% | 0.01% | +9.1% |
| Q1 2023 | $899,183 | -9.7% | 12,120 | +0.9% | 0.01% | -15.4% |
| Q4 2022 | $995,886 | +16.8% | 12,016 | +300.0% | 0.01% | +8.3% |
| Q3 2022 | $853,000 | -18.5% | 3,004 | -0.5% | 0.01% | -25.0% |
| Q2 2022 | $1,047,000 | -74.9% | 3,020 | -68.6% | 0.02% | -62.8% |
| Q1 2022 | $4,166,000 | -16.0% | 9,621 | +0.4% | 0.04% | -21.8% |
| Q4 2021 | $4,957,000 | -14.6% | 9,581 | -20.0% | 0.06% | -16.7% |
| Q3 2021 | $5,806,000 | -39.5% | 11,981 | -43.8% | 0.07% | -38.9% |
| Q2 2021 | $9,604,000 | +95.9% | 21,331 | +66.2% | 0.11% | +86.2% |
| Q1 2021 | $4,902,000 | +22.1% | 12,835 | +1.5% | 0.06% | +9.4% |
| Q4 2020 | $4,014,000 | +25.9% | 12,640 | -1.8% | 0.05% | +12.8% |
| Q3 2020 | $3,188,000 | -14.8% | 12,869 | -9.2% | 0.05% | -14.5% |
| Q2 2020 | $3,742,000 | +38.3% | 14,169 | -0.7% | 0.06% | +17.0% |
| Q1 2020 | $2,705,000 | -14.3% | 14,266 | -0.7% | 0.05% | +6.8% |
| Q4 2019 | $3,155,000 | +3.1% | 14,371 | -8.1% | 0.04% | +10.0% |
| Q3 2019 | $3,059,000 | -4.3% | 15,633 | +2.0% | 0.04% | -7.0% |
| Q2 2019 | $3,197,000 | +7.9% | 15,333 | +2.8% | 0.04% | +2.4% |
| Q1 2019 | $2,962,000 | +37.2% | 14,917 | 0.0% | 0.04% | +23.5% |
| Q4 2018 | $2,159,000 | -28.5% | 14,917 | +0.9% | 0.03% | -19.0% |
| Q3 2018 | $3,018,000 | +39.7% | 14,785 | +1.3% | 0.04% | +31.2% |
| Q2 2018 | $2,160,000 | +2.1% | 14,600 | +4.2% | 0.03% | 0.0% |
| Q1 2018 | $2,116,000 | -39.0% | 14,007 | -49.4% | 0.03% | +18.5% |
| Q4 2017 | $3,467,000 | +108.4% | 27,677 | +101.1% | 0.03% | 0.0% |
| Q3 2017 | $1,664,000 | +3.7% | 13,763 | +0.8% | 0.03% | 0.0% |
| Q2 2017 | $1,605,000 | +20.5% | 13,656 | +4.2% | 0.03% | +3.8% |
| Q1 2017 | $1,332,000 | +0.4% | 13,101 | +1.6% | 0.03% | -3.7% |
| Q4 2016 | $1,327,000 | -5.3% | 12,901 | +0.8% | 0.03% | -10.0% |
| Q3 2016 | $1,402,000 | +0.4% | 12,801 | +3.4% | 0.03% | -3.2% |
| Q2 2016 | $1,396,000 | +22.2% | 12,381 | +2.5% | 0.03% | +19.2% |
| Q1 2016 | $1,142,000 | +9.4% | 12,079 | +4.1% | 0.03% | +4.0% |
| Q4 2015 | $1,044,000 | -2.6% | 11,598 | 0.0% | 0.02% | -7.4% |
| Q3 2015 | $1,072,000 | -6.1% | 11,598 | 0.0% | 0.03% | 0.0% |
| Q2 2015 | $1,142,000 | -0.1% | 11,598 | +1.8% | 0.03% | 0.0% |
| Q1 2015 | $1,143,000 | +13.5% | 11,398 | +4.6% | 0.03% | +12.5% |
| Q4 2014 | $1,007,000 | – | 10,898 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |